A COMPARITIVE STUDY TO DETERMINE EFFICACY AND SAFETY OF ADD ON LOW- FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) VERSUS SSRI(SELECTIVE SEROTONIN REUPTAKE INHIBITORS) IN GENERALIZED ANXIETY DISORDER-A RCT

DETERMINE EFFICACY AND SAFETY OF ADD ON LOW- FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) VERSUS SSRI(SELECTIVE SEROTONIN REUPTAKE INHIBITORS) IN GENERALIZED ANXIETY DISORDER-A RCT - yes

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086488

Enrollment

Registered

2025-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G- Mental Health Health Condition 2: F01-F99- Mental, Behavioral and Neurodevelopmental disorders

Interventions

Intervention1: escitalopram-10mg Vs rTMS: escitalopram-10mg for 3months 1hz rTMS 20 session Control Intervention1: escitalopram-10mg Vs rTMS: escitalopram-10mg for 3months 1hz rTMS 20 session

Eligibility

Inclusion criteria

Inclusion criteria: Meeting the diagnostic criteria for generalized anxiety disorder in the DSM-5 Having HAM-A score of more than 14. Age- 18 years of age to 60 years of age. Patients showing no or minimal clinical improvement after at least 6 weeks of treatment with 1 SSRI S Patients being Right handed. Having no abnormalities on physical examination of nervous system. Patient giving written informed consent.

Exclusion criteria

Exclusion criteria: Having other types of anxiety diagnosed based on DSM-5 Scoring more than 20 on HAM D. Having secondary anxiety due to other organic diseases. Having a history of brain surgery and epilepsy. Having metallic foreign bodies, such as cardiac pacemakers and stents. Being a pregnant or lactating patient.

Design outcomes

Primary

Measure	Time frame
TO OBSERVE IMPROVED SYMPTOMS IN PATIENTS WITH GENERALISED ANXIETY DISORDER Timepoint: 12 months	—

Secondary

Measure	Time frame
TO OBSERVE BETTER QUALITY OF LIFE IN PATIENTS WITH GENERALISED ANXIETY DISORDERTimepoint: 12 months	—

Countries

India

Contacts

Public ContactJitendriya Biswal

IMSandSUMHOSPITAL(SOADEEMEDUNIVERSITY)

jitendriyabiswal@soa.ac.in9337270395

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026